Allergan, Inc.

Allergan, Inc.
	Allergan headquarters in Irvine
Company type	Public
Traded as	NYSE: AGN
Industry	Eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics
Founded	1948
Defunct	2015
Fate	Acquired by Actavis plc in 2015, who then renamed the group as Allergan plc
Successor	Actavis
Headquarters	Irvine, California, U.S.
Area served	Over 100 Countries
Key people	Paul Bisaro (executive chairman)
Revenue	$6.2 billion (2013)
Number of employees	11400 (2013)
Parent	Allergan plc
Website	www.allergan.com

Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970.^[2] It ceased operation in 2015 when it was acquired by Irish-based Actavis plc (itself a 2013 U.S. tax inversion to Ireland), who then renamed the group as Allergan plc.^[3]

^ ^a ^b "Allergan Today". allergan.co.uk.
^ Pflanzer, Lydia Ramsey. "How Allergan went from a tiny Los Angeles eye care company to the biggest takeover target of 2015". Business Insider. Retrieved 2020-09-10.
^ "From Actavis to Allergan: One pharma company's wild dealmaking journey". Forbes Magazine. 30 July 2015. For a master class in mergers and acquisitions, one need only look at the company formerly known as Actavis. Now called Allergan, after its $70 billion acquisition of that maker of Botox last fall, the pharmaceutical firm has undertaken a dizzying series of deals in just the last few years, reinventing and renaming itself in a fashion that might make the artist formerly known as The Artist Formerly Known As Prince proud.

[allergan.co.uk-1] "Allergan Today". allergan.co.uk.

[2] Pflanzer, Lydia Ramsey. "How Allergan went from a tiny Los Angeles eye care company to the biggest takeover target of 2015". Business Insider. Retrieved 2020-09-10.

[3] "From Actavis to Allergan: One pharma company's wild dealmaking journey". Forbes Magazine. 30 July 2015. For a master class in mergers and acquisitions, one need only look at the company formerly known as Actavis. Now called Allergan, after its $70 billion acquisition of that maker of Botox last fall, the pharmaceutical firm has undertaken a dizzying series of deals in just the last few years, reinventing and renaming itself in a fashion that might make the artist formerly known as The Artist Formerly Known As Prince proud.

[1]

[2]

[3]